ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
부데소니드 흡입기 시장 규모는 향후 몇 년 동안 강력한 성장세를 보일 것으로 예상되며, 2029년까지 8.7%의 CAGR로 96억 8,000만 달러에 달할 것으로 예상됩니다. 예측 기간 동안의 성장은 호흡기 치료제 개발에 대한 투자 증가, 호흡기 치료에서 맞춤형 의료에 대한 수요 증가, 원격의료 및 전자 처방의 사용 확대, 조기 진단 및 치료에 대한 인식 증가, 흡입기 병용요법에 대한 선호도 증가에 기인하는 것으로 보입니다. 이 기간의 주요 동향으로는 약물전달을 개선하기 위한 첨단 제형 기술, 디지털 추적 기능을 갖춘 스마트 흡입기의 혁신, 호흡기 건강 관리에 AI와 IoT의 통합, 환자 중심 약물 설계의 발전, 순응도 모니터링을 위한 모바일 앱의 통합 등이 있습니다.
호흡기질환의 유병률 증가는 향후 몇 년 동안 부데소니드 흡입기 시장의 성장을 촉진할 것으로 예상됩니다. 폐와 호흡기에 영향을 미치는 호흡기질환은 호흡을 어렵게 하고 종종 기침, 천명음, 호흡곤란 등의 증상을 유발합니다. 이러한 질환에는 천식, 만성폐쇄성폐질환(COPD), 폐렴, 기관지염, 폐 감염 등이 포함됩니다. 호흡기질환의 증가는 대기오염의 증가로 인해 기도를 자극하고 폐 기능을 악화시키는 유해한 오염물질에 노출되는 대기오염의 증가에 크게 기인합니다. 부데소니드 흡입제는 항염증제를 폐에 직접 투여하여 이러한 질환을 장기적으로 관리하는 데 도움을 줄 수 있습니다. 컴팩트한 디자인으로 사용 편의성과 휴대성을 보장하고 재발을 방지하며 호흡기 건강을 개선합니다. 예를 들어, 호주 통계청에 따르면 호주의 만성폐쇄성폐질환(COPD) 유병률은 2021년 2.4%에서 2022년 2.5%로 증가했습니다. 결과적으로 호흡기질환의 유병률 증가는 부데소니드 흡입기 시장의 성장에 기여하고 있습니다.
부데소니드 흡입기 시장의 주요 기업들은 저렴한 가격으로 호흡기질환을 치료할 수 있도록 제네릭 의약품과 같은 혁신적인 제품 개발에 점점 더 많은 노력을 기울이고 있습니다. 제네릭 흡입제는 브랜드 제품과 동일한 활성 성분, 용량 및 치료 효과를 포함하는 비브랜드 제품의 대체품이지만 가격은 더 저렴합니다. 예를 들어, 2023년 7월 Viatris Inc.는 Kindeva Drug Delivery L.P.와 제휴하여 FDA가 승인한 최초의 심비코트 제네릭 의약품인 Breyna(부데소니드 푸마르산 포르모테롤 이수화합물) 흡입용 에어로졸을 출시했습니다. 이 약물과 기기의 조합은 부데소니드로 기도의 염증을 억제하고, 호르몬인 포르모테롤로 기도 주변 근육을 이완시켜 천식과 COPD를 치료하도록 설계되어 환자들에게 보다 합리적인 가격의 치료 옵션을 제공합니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향과 전략
제4장 시장 - 금리, 인플레이션, 지정학, 무역 전쟁과 관세, 그리고 코로나와 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석과 전략 분석 프레임워크
세계의 부데소니드 흡입기 PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인, 억제요인)
최종 이용 산업 분석
세계의 부데소니드 흡입기 시장 : 성장률 분석
세계의 부데소니드 흡입기 시장 실적 : 규모와 성장, 2019-2024년
세계의 부데소니드 흡입기 시장 예측 : 규모와 성장, 2024-2029년, 2034년
세계의 부데소니드 흡입기 전체 시장(TAM)
제6장 시장 세분화
세계의 부데소니드 흡입기 시장 : 제품 유형별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
정량 분무식 흡입기(MDI)
건조 분말 흡입기(DPI)
네블라이저
배합 흡입기
세계의 부데소니드 흡입기 시장 : 제형별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
에어로졸
드라이 파우더
서스펜션
스프레이
세계의 부데소니드 흡입기 시장 : 적응증별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
천식
만성폐쇄성폐질환
알레르기성 비염
세계의 부데소니드 흡입기 시장 : 최종사용자별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
병원
외래 진료소
재택 케어 설정
약국
세계의 부데소니드 흡입기 시장 : 정량 분무식 흡입기 하위 세분화 : 유형별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
가압식 정량 분무식 흡입기
호흡 작동식 정량 분무식 흡입기
스페이서 대응 정량 분무식 흡입기
하이드로플루오로알칸 분사제형 정량 분무식 흡입기
세계의 부데소니드 흡입기 시장 : 건조 분말 흡입기 하위 세분화 : 유형별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
일회 투여 건조 분말 흡입기
다회 투여 건조 분말 흡입기
캡슐형 건조 분말 흡입기
레저버형 건조 분말 흡입기
세계의 부데소니드 흡입기 시장 : 네블라이저 하위 세분화 : 유형별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
제트 네블라이저
초음파 네블라이저
메시 네블라이저
홈케어용 네블라이저
병원용 네블라이저
세계의 부데소니드 흡입기 시장 : 배합 흡입기 하위 세분화 : 유형별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
부데소니드, 포르모테롤 배합 흡입기
부데소니드, 살메테롤 배합 흡입기
부데소니드, 글리코피롤, 포르모테롤 배합 흡입기
부데소니드, 빌란테롤 배합 흡입기
제7장 지역별·국가별 분석
세계의 부데소니드 흡입기 시장 : 지역별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
세계의 부데소니드 흡입기 시장 : 국가별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 개요
부데소니드 흡입기 시장 : 경쟁 구도
부데소니드 흡입기 시장 : 기업 개요
AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis
GSK plc Overview, Products and Services, Strategy and Financial Analysis
Takeda Pharmaceutical Company Limited Overview, Products and Services, Strategy and Financial Analysis
Viatris Inc. Overview, Products and Services, Strategy and Financial Analysis
Teva Pharmaceutical Industries Ltd. Overview, Products and Services, Strategy and Financial Analysis
제31장 기타 주요 기업과 혁신적 기업
Boehringer Ingelheim International GmbH
Sandoz International GmbH
Bausch Health Companies Inc.
Sun Pharmaceutical Industries Ltd.
Synmosa Biopharma Corporation
Chiesi Farmaceutici S.p.A.
Aurobindo Pharma Limited
Cipla Limited
Hikma Pharmaceuticals PLC
Lupin Limited
Orion Corporation
Nephron Pharmaceuticals Corporation
Curia Global Inc.
Kindeva Drug Delivery L.P.
Minakem SAS
제32장 세계의 시장 경쟁 벤치마킹과 대시보드
제33장 주요 인수합병
제34장 최근의 시장 동향
제35장 시장 잠재력이 높은 국가, 부문, 전략
부데소니드 흡입기 시장 2029년 : 새로운 기회를 제공하는 국가
부데소니드 흡입기 시장 2029년 : 새로운 기회를 제공하는 부문
부데소니드 흡입기 시장 2029년 : 성장 전략
시장 동향에 기반한 전략
경쟁 전략
제36장 부록
ksm
영문 목차
영문목차
The budesonide inhaler is a respiratory device that delivers the corticosteroid medication budesonide directly to the lungs. It helps reduce airway inflammation, making breathing easier. The budesonide inhaler is typically prescribed for the long-term management of respiratory diseases.
The main types of products in the budesonide inhaler market include metered-dose inhalers (MDIs), dry powder inhalers (DPIs), nebulizers, and combination inhalers. Metered-dose inhalers (MDIs) are handheld medical devices that deliver a precise amount of medication directly to the lungs in the form of a short burst of aerosolized medicine. The available dosage forms include aerosols, dry powder, suspension, and spray, each indicated for different conditions such as asthma, chronic obstructive pulmonary disease (COPD), and allergic rhinitis. The primary end-users of these products include hospitals, outpatient clinics, home care settings, and pharmacies.
The budesonide inhaler market research report is one of a series of new reports from The Business Research Company that provides budesonide inhaler market statistics, including budesonide inhaler industry global market size, regional shares, competitors with a budesonide inhaler market share, detailed budesonide inhaler market segments, market trends and opportunities, and any further data you may need to thrive in the budesonide inhaler industry. This budesonide inhaler market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The budesonide inhaler market size has grown strongly in recent years. It will grow from $6.37 billion in 2024 to $6.94 billion in 2025 at a compound annual growth rate (CAGR) of 9.0%. The growth during the historic period can be attributed to heightened awareness of inhalation therapies, growing adoption of corticosteroid treatments, rising air pollution levels leading to respiratory problems, increasing demand for minimally invasive drug delivery methods, and a stronger focus on home healthcare solutions.
The budesonide inhaler market size is expected to see strong growth in the next few years. It will grow to $9.68 billion in 2029 at a compound annual growth rate (CAGR) of 8.7%. The growth in the forecast period can be attributed to increasing investments in respiratory drug development, rising demand for personalized medicine in respiratory care, greater use of telemedicine and e-prescriptions, heightened awareness of early diagnosis and treatment, and a growing preference for combination inhaler therapies. Key trends during this period include advanced formulation techniques for improved drug delivery, innovations in smart inhalers with digital tracking, the integration of AI and IoT in respiratory health management, advancements in patient-centric drug designs, and the incorporation of mobile apps for adherence monitoring.
The growing incidence of respiratory disorders is expected to drive the expansion of the budesonide inhaler market in the coming years. Respiratory disorders, which affect the lungs and airways, can make breathing difficult and often lead to symptoms such as coughing, wheezing, and shortness of breath. These conditions include asthma, chronic obstructive pulmonary disease (COPD), pneumonia, bronchitis, and lung infections. The rise in respiratory disorders is largely attributed to increasing air pollution, which exposes individuals to harmful pollutants that irritate the airways and worsen lung function. Budesonide inhalers help manage these disorders by delivering anti-inflammatory medication directly to the lungs, providing long-term control. Their compact design ensures ease of use and portability, reducing flare-ups and improving respiratory health. For example, according to the Australian Bureau of Statistics, the prevalence of chronic obstructive pulmonary disease (COPD) in Australia increased from 2.4% in 2021 to 2.5% in 2022. As a result, the growing prevalence of respiratory disorders is fueling the growth of the budesonide inhaler market.
Leading companies in the budesonide inhaler market are increasingly focused on developing innovative products, such as generic versions, to enhance affordability and broaden access to treatment for respiratory conditions. Generic inhalers are non-branded alternatives that contain the same active ingredients, dosage, and therapeutic effects as their branded counterparts, but typically at a lower price. For example, in July 2023, Viatris Inc., in partnership with Kindeva Drug Delivery L.P., launched Breyna (budesonide and formoterol fumarate dihydrate) inhalation aerosol, the first FDA-approved generic version of Symbicort. This drug-device combination is designed to treat asthma and COPD by reducing airway inflammation with budesonide, while formoterol relaxes the muscles around the airways, offering a more affordable option for patients.
In January 2025, Molex, a US-based electronics company, acquired Vectura Group Ltd. for an undisclosed sum. Through this acquisition, Molex aims to establish a leading position in inhalation drug delivery by combining Phillips Medisize's manufacturing expertise with Vectura's specialization in inhalation devices and formulation development. This move will enhance Molex's ability to deliver innovative therapies for respiratory conditions. Vectura Group, based in the UK, is known for its work in developing inhalation drug delivery systems, including those used to administer budesonide.
Major players in the budesonide inhaler market are AstraZeneca plc, GSK plc, Takeda Pharmaceutical Company Limited, Viatris Inc., Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim International GmbH, Sandoz International GmbH, Bausch Health Companies Inc., Sun Pharmaceutical Industries Ltd., Synmosa Biopharma Corporation, Chiesi Farmaceutici S.p.A., Aurobindo Pharma Limited, Cipla Limited, Hikma Pharmaceuticals PLC, Lupin Limited, Orion Corporation, Nephron Pharmaceuticals Corporation, Curia Global Inc., Kindeva Drug Delivery L.P., Minakem SAS, Axplora Group GmbH, Cosmo Pharmaceuticals N.V., Manus Aktteva Biopharma LLP, Tovec Pharma Pvt. Ltd., Nutra Respiro Healthcare Pvt. Ltd.
North America was the largest region in the budesonide inhaler market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in budesonide inhaler report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the budesonide inhaler market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The budesonide inhaler market consists of sales of soft mist inhalers, nasal inhalers, budesonide repulse, oral inhalation capsules, and transdermal inhalation systems. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Budesonide Inhaler Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on budesonide inhaler market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for budesonide inhaler ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The budesonide inhaler market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
4) Combination Inhalers: Budesonide And Formoterol Inhalers; Budesonide And Salmeterol Inhalers; Budesonide, Glycopyrrolate, And Formoterol Inhalers; Budesonide And Vilanterol Inhalers
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Budesonide Inhaler Market Characteristics
3. Budesonide Inhaler Market Trends And Strategies
4. Budesonide Inhaler Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
5. Global Budesonide Inhaler Growth Analysis And Strategic Analysis Framework
5.1. Global Budesonide Inhaler PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Budesonide Inhaler Market Growth Rate Analysis
5.4. Global Budesonide Inhaler Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Budesonide Inhaler Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Budesonide Inhaler Total Addressable Market (TAM)
6. Budesonide Inhaler Market Segmentation
6.1. Global Budesonide Inhaler Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Metered-Dose Inhalers (MDIs)
Dry Powder Inhalers (DPIs)
Nebulizers
Combination Inhalers
6.2. Global Budesonide Inhaler Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Aerosols
Dry Powder
Suspension
Spray
6.3. Global Budesonide Inhaler Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Asthma
Chronic Obstructive Pulmonary Disease
Allergic Rhinitis
6.4. Global Budesonide Inhaler Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospitals
Outpatient Clinics
Homecare Settings
Pharmacies
6.5. Global Budesonide Inhaler Market, Sub-Segmentation Of Metered-Dose Inhalers, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
6.6. Global Budesonide Inhaler Market, Sub-Segmentation Of Dry Powder Inhalers, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Single-Dose Dry Powder Inhalers
Multi-Dose Dry Powder Inhalers
Capsule-Based Dry Powder Inhalers
Reservoir-Based Dry Powder Inhalers
6.7. Global Budesonide Inhaler Market, Sub-Segmentation Of Nebulizers, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Jet Nebulizers
Ultrasonic Nebulizers
Mesh Nebulizers
Homecare Nebulizers
Hospital-Use Nebulizers
6.8. Global Budesonide Inhaler Market, Sub-Segmentation Of Combination Inhalers, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Budesonide And Formoterol Inhalers
Budesonide And Salmeterol Inhalers
Budesonide, Glycopyrrolate, And Formoterol Inhalers
Budesonide And Vilanterol Inhalers
7. Budesonide Inhaler Market Regional And Country Analysis
7.1. Global Budesonide Inhaler Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Budesonide Inhaler Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
